Increasing CAR T-cell Use in R/R DLBC Lymphoma: Marin F. Xavier, MD; John M. Burke, MD
Experts discuss recommendations to increase the uptake of CAR T-cell therapies into clinical practice and relapsed/refractory diffuse large B-cell lymphoma.
CAR T or Transplant in DLBC Lymphoma: John M. Burke, MD; Marin F. Xavier, MD
Experts discussed using newer targeted treatment approaches as frontline therapy instead of transplant in patients with relapsed/refractory diffuse large B-cell lymphoma.
CD19 CAR T and Therapies in LBC Lymphoma: Marin F. Xavier, MD; John M. Burke, MD
Experts discussed using CD19-targeted agents in patients with various subtypes of diffuse large B-cell lymphoma.
CAR T and Other Approaches for Patients with R/R DLBC Lymphoma
Loretta Nastoupil, MD, and John Burke, MD, discussed treating relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Dr. Burke on the Potential of Time-Limited BTK Inhibitor Therapy in B-Cell Malignancies
John M. Burke, MD, discusses the potential benefits of time-limited therapy with BTK inhibitors in B-cell malignancies.
